Anavex Life Sciences Corp. (AVXL): Operating Cash Flow
-$39.04M
Year ended 2025-09-30
-$29.29M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-09-30 | -$39.04M | n/m | 2026-08-28, From 2024-10-01 |
| 2024-09-30 | -$30.81M | n/m | 2026-08-28, From 2023-10-01 |
| 2023-09-30 | -$27.79M | n/m | 2026-08-28, From 2022-10-01 |
| 2022-09-30 | -$24.24M | n/m | 2023-11-27, From 2021-10-01 |
| 2021-09-30 | -$30.38M | n/m | 2023-11-27, From 2020-10-01 |
| 2020-09-30 | -$21.29M | n/m | 2022-11-28, From 2019-10-01 |
| 2019-09-30 | -$18.53M | n/m | 2020-12-28, From 2018-10-01 |
| 2018-09-30 | -$12.58M | n/m | 2019-12-16, From 2017-10-01 |
| 2017-09-30 | -$9.02M | n/m | 2019-01-25, From 2016-10-01 |
| 2016-09-30 | -$9.24M | n/m | 2019-01-25, From 2015-10-01 |
| 2015-09-30 | -$4.23M | n/m | 2017-12-11, From 2014-10-01 |
| 2014-09-30 | -$2.66M | n/m | 2014-12-29, From 2013-10-01 |
| 2013-09-30 | -$777.6K | n/m | 2014-12-29, From 2012-10-01 |
| 2012-09-30 | -$1.69M | n/m | 2013-12-30, From 2011-10-01 |
| 2011-09-30 | -$3.80M | n/m | 2012-12-31, From 2010-10-01 |
| 2010-09-30 | -$4.59M | n/a | 2011-12-22, From 2009-10-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Anavex Life Sciences Corp. (AVXL) | 2025-09-30 | -$39.04M | n/m |
| Surrozen, Inc. (SRZN) | 2025-12-31 | -$30.24M | n/m |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | -$18.92M | n/m |
| Zura Bio Ltd (ZURA) | 2025-12-31 | -$64.81M | n/m |
| Quince Therapeutics, Inc. (QNCX) | 2025-12-31 | -$41.42M | n/m |
| aTYR PHARMA INC (ATYR) | 2025-12-31 | -$61.99M | n/m |
| Humacyte, Inc. (HUMA) | 2025-12-31 | -$105.04M | n/m |
| LeonaBio, Inc. (LONA) | 2025-12-31 | -$45.73M | n/m |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | -$82.50M | n/m |
Compare AVXL, SRZN, LCTX, ZURA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗